Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296903 | 1.00 | KEAP1 (0.44) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL21750024 | 0.84 | KEAP1 (0.45) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL17275022 | 0.83 | CES2 (0.38) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL30739599 | 0.83 | CES2 (0.38) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL2203971 | 0.83 | KEAP1 (0.44) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL365563 | 0.81 | CES2 (0.47) | CES2CES1KDM4EKMT2AMEN1 | |
| SCHEMBL31258574 | 0.81 | CES2 (0.47) | CES2CES1KDM4EKMT2AMEN1 | |
| SCHEMBL19565666 | 0.81 | ALDH1A1 (0.38) | KEAP1CES2CES1HDAC1HDAC6 | |
| SCHEMBL855460 | 0.81 | THRB (0.42) | KEAP1CES2CES1KDM4EKMT2A | |
| SCHEMBL20575325 | 0.79 | DPP4 (0.50) | KEAP1KDM4EKMT2AGFERRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150597-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT | JNC株式会社 | 2024-07-18 | — | — | WO | disclosed |
| CN-115745878-A | Fluorine-containing pyridine bisamide insecticide and acaricide | 青岛科技大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| EP-3676263-B1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. | 2021-07-06 | — | — | US | disclosed |
| EP-3676263-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2020-07-08 | — | — | EP | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2020-06-11 | — | — | US | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1911751-A1 | AMIDE DERIVATIVE AND PESTICIDE CONTAINING SUCH COMPOUND | Mitsui Chemicals, Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0062659-A4 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES. | FMC CORP (US) | 1983-01-14 | — | — | EP | disclosed |
| EP-0062659-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC Corporation (US) | 1982-10-20 | — | — | EP | disclosed |
| US-4339457-A | OF CYCLOPROPANECARBOXYLIC ACIDS, INSECTICIDES, MITICIDES | FMC CORPORATION (US) | 1982-07-13 | — | — | US | disclosed |
| WO-1982001368-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC CORP (US) | 1982-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | KEAP1 77/4885CES2 749/4885CES1 955/4885 |
| US-11053230-B2 | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | KEAP1 134/4885CES2 788/4885CES1 472/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KEAP1 77/4885CES2 749/4885CES1 955/4885 |
| US-20200181128-A1 | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | KEAP1 134/4885CES2 788/4885CES1 472/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | KEAP1 77/4885CES2 749/4885CES1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.